Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update
Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference